Fabry Disease Treatment Market Size By Treatment Type (Enzyme Replacement Therapy, By End-use }, Chaperone Therapy), By Industry Analysis Report, Price Trends, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022

Description

List of Tables

The global Fabry disease treatment market size is expected to increase considerably over 2022-2030, on account of the rising initiatives to support early-disease diagnosis and treatments. A notable example is an initiative launched by the National Kidney Foundation and the FSIG (Fabry Support & Information Group) to inform the U.S. FDA about the perspectives of living with Fabry disease.

Patients with rare genetic diseases are facing a challenging path to proper diagnosis due to low disease awareness. To reduce barriers to comprehensive testing methods, several projects have been developed worldwide. For example, Sanofi Genzyme and PerkinElmer Genomics launched the Lantern Project to facilitate the screening of suspected Fabry and other disorders, which is anticipated to contribute to market expansion over the projected timeframe.

The Fabry disease treatment industry is bifurcated in terms of treatment type and regional landscape.

Based on the treatment type, the market is segregated into chaperone therapy and enzyme replacement therapy (ERT). Among these, the chaperone therapy segment is set to account for a considerable market share by 2030. This is attributed to the capability of small-molecule chaperones to bind to active sites of mutant forms of the alpha-galactosidase A enzyme, stabilize them, and restore the function of the natural enzyme.

The binding and stabilization can help facilitate the proper trafficking of alpha-Gal A to the lysosomes, enabling the restoration of enzymatic activity of the mutant protein and lowering the rate of accumulation of glycolipids in organ cells. These benefits will likely encourage healthcare professionals to rely on chaperone therapy for Fabry disease diagnosis and in turn, drive the segmental expansion.

On the regional front, the Europe Fabry disease treatment industry is expected to register considerable revenue by 2030. This can be credited to the rising adult population and the potential increase in the prevalence of late-onset Fabry disease symptoms. According to data from Eurostat, the number of people aged 80 years and above is likely to grow by two and a half times between 2021 and 2100. Since elderly people are at higher risk of Fabry disease, this population rise may assert a positive influence on regional market trends.

Likewise, the Asia Pacific is also anticipated to emerge as a lucrative revenue pocket for the Fabry disease treatment market over the estimated timeline. The regional market growth is driven by the growing emphasis on healthcare infrastructure expansion projects.

For example, in October 2021, AIIB (Asian Infrastructure Investment Bank) announced its support for India, in its efforts to ramp up healthcare infrastructure facilities to meet future health challenges. AIIB also revealed its collaboration with the Indian government to form climate-resilient infrastructure projects. Initiatives such as these are expected to advance Fabry disease therapy and consequently foster regional Fabry disease treatment industry development over the years ahead.

Product Code: 4237

Chapter 1 Methodology & Scope

1.1 Market definitions
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Fabry disease treatment industry 360 degree synopsis, 2017 - 2030 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Treatment type trends
- 2.1.3 Regional trends

Chapter 3 Fabry Disease Treatment Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Rising cases of Fabry disease across the globe
  - 3.3.1.2 Growing awareness among specialist and physicians
  - 3.3.1.3 Advancements in Fabry disease treatment therapies
  - 3.3.1.4 Rising health awareness and demand for early-stage diagnosis
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 High treatment cost
3.4 Growth potential analysis
- 3.4.1 By treatment
3.5 COVID- 19 impact analysis
3.6 Future market trends
3.7 Technology landscape
3.8 Pricing analysis
3.9 Brand analysis
3.10 Gap analysis
3.11 Product pipeline analysis
3.12 Reimbursement scenario
3.13 Regulatory landscape
- 3.13.1 U.S.
- 3.13.2 Europe
3.14 Porter's Analysis
3.15 Competitive landscape, 2021
- 3.15.1 Company matrix analysis, 2021
- 3.15.2 Company market share analysis, 2021
- 3.15.3 Global
- 3.15.4 North America
- 3.15.5 Europe
- 3.15.6 Asia Pacific
- 3.15.7 Latin America
- 3.15.8 MEA
3.16 PESTLE Analysis

Chapter 4 Fabry Disease Treatment Market, By Treatment Type

4.1 Key segment trends
4.2 Enzyme Replacement Therapy (ERT)
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.2 By Drug Type
  - 4.2.2.1 Agalidase Alpa
    - 4.2.2.1.1 Market size, by region, 2017 - 2030 (USD Million)
  - 4.2.2.2 Agalidase Beta
    - 4.2.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
- 4.2.3 By End-use
  - 4.2.3.1 Physician office
    - 4.2.3.1.1 Market size, by region, 2017 - 2030 (USD Million)
  - 4.2.3.2 Home settings
    - 4.2.3.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Chaperone Therapy
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Fabry Disease Treatment Market, By Region

5.1 Key regional trends
5.2 North America
- 5.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.2.2 Market size, by treatment type, 2017 - 2030 (USD Million)
  - 5.2.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
  - 5.2.2.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.2.3 U.S.
  - 5.2.3.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.2.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.2.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.2.4 Canada
  - 5.2.4.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.2.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.2.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3 Europe
- 5.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.3.2 Market size, by treatment type, 2017 - 2030 (USD Million)
  - 5.3.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
  - 5.3.2.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.3.3 Germany
  - 5.3.3.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.3.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.3.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.3.4 UK
  - 5.3.4.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.3.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.3.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.3.5 France
  - 5.3.5.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.3.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.3.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.3.6 Spain
  - 5.3.6.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.3.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.3.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.3.7 Italy
  - 5.3.7.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.3.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.3.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4 Asia Pacific
- 5.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.4.2 Market size, by treatment type, 2017 - 2030 (USD Million)
  - 5.4.2.1 Market size, by drug type, 2017 - 2030 (USD Million)
  - 5.4.2.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.4.3 Japan
  - 5.4.3.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.4.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.4.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.4.4 China
  - 5.4.4.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.4.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.4.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.4.5 India
  - 5.4.5.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.4.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.4.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.4.6 Australia
  - 5.4.6.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.4.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.4.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
- 5.4.7 South Korea
  - 5.4.7.1 Market size, by treatment type, 2017-2030 (USD Million)
    - 5.4.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
    - 5.4.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.5 ROW
- 5.5.1 Market size, by treatment type, 2017 - 2030 (USD Million)
  - 5.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
  - 5.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)

Chapter 6 Company Profiles

6.1 Competitive dashboard, 2021
6.2 Sanofi
- 6.2.1 Business Overview
- 6.2.2 Financial Data
- 6.2.3 Product Landscape
- 6.2.4 Strategic Outlook
- 6.2.5 SWOT Analysis
6.3 Takeda
- 6.3.1 Business Overview
- 6.3.2 Financial Data
- 6.3.3 Product Landscape
- 6.3.4 Strategic Outlook
- 6.3.5 SWOT Analysis
6.4 Amicus Therapeutics
- 6.4.1 Business Overview
- 6.4.2 Financial Data
- 6.4.3 Product Landscape
- 6.4.4 Strategic Outlook
- 6.4.5 SWOT Analysis
6.5 ISU Abaxis
- 6.5.1 Business Overview
- 6.5.2 Financial Data
- 6.5.3 Product Landscape
- 6.5.4 Strategic Outlook
- 6.5.5 SWOT Analysis
6.6 JCR Pharmaceuticals Co Ltd.
- 6.6.1 Business Overview
- 6.6.2 Financial Data
- 6.6.3 Product Landscape
- 6.6.4 Strategic Outlook
- 6.6.5 SWOT Analysis